HRP20010615B1 - Pharmaceutical compositions containing proton pump inhibitors - Google Patents

Pharmaceutical compositions containing proton pump inhibitors

Info

Publication number
HRP20010615B1
HRP20010615B1 HR20010615A HRP20010615A HRP20010615B1 HR P20010615 B1 HRP20010615 B1 HR P20010615B1 HR 20010615 A HR20010615 A HR 20010615A HR P20010615 A HRP20010615 A HR P20010615A HR P20010615 B1 HRP20010615 B1 HR P20010615B1
Authority
HR
Croatia
Prior art keywords
pharmaceutical compositions
compositions containing
fatty acids
proton pump
pump inhibitors
Prior art date
Application number
HR20010615A
Other languages
English (en)
Croatian (hr)
Inventor
Freehauf Keith
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20010615A2 publication Critical patent/HRP20010615A2/hr
Publication of HRP20010615B1 publication Critical patent/HRP20010615B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20010615A 1999-02-23 2001-08-23 Pharmaceutical compositions containing proton pump inhibitors HRP20010615B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12125399P 1999-02-23 1999-02-23
PCT/US2000/004170 WO2000050038A1 (en) 1999-02-23 2000-02-18 Pharmaceutical composition containing proton pump inhibitors

Publications (2)

Publication Number Publication Date
HRP20010615A2 HRP20010615A2 (en) 2002-12-31
HRP20010615B1 true HRP20010615B1 (en) 2011-03-31

Family

ID=22395498

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20010615A HRP20010615B1 (en) 1999-02-23 2001-08-23 Pharmaceutical compositions containing proton pump inhibitors

Country Status (31)

Country Link
US (1) US6316481B1 (pt)
EP (1) EP1156806B1 (pt)
JP (1) JP2002537337A (pt)
KR (1) KR100701448B1 (pt)
CN (1) CN1227009C (pt)
AR (1) AR029615A1 (pt)
AT (1) ATE263562T1 (pt)
AU (1) AU771061B2 (pt)
BG (1) BG65291B1 (pt)
BR (1) BR0008403A (pt)
CA (1) CA2362932C (pt)
CO (1) CO5140102A1 (pt)
CZ (1) CZ301647B6 (pt)
DE (1) DE60009675T2 (pt)
DK (1) DK1156806T3 (pt)
EA (1) EA004683B1 (pt)
ES (1) ES2216870T3 (pt)
HK (1) HK1041650A1 (pt)
HR (1) HRP20010615B1 (pt)
HU (1) HU228181B1 (pt)
IL (1) IL144131A0 (pt)
ME (1) ME00864B (pt)
NO (1) NO328863B1 (pt)
NZ (1) NZ512771A (pt)
PL (1) PL195783B1 (pt)
PT (1) PT1156806E (pt)
RS (1) RS50023B (pt)
SK (1) SK286371B6 (pt)
TW (1) TW587936B (pt)
WO (1) WO2000050038A1 (pt)
ZA (1) ZA200106104B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6852739B1 (en) 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
NZ522450A (en) 2000-05-30 2004-07-30 Merial Ltd Methods for prevention of ulcers
BR0115989A (pt) 2000-12-07 2004-01-13 Altana Pharma Ag Preparação farmacêutica na forma de uma suspensão compreendendo um ingrediente ativo instável a ácido
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
CA2430816C (en) 2000-12-07 2012-05-15 Altana Pharma Ag Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
JP4634144B2 (ja) 2002-08-01 2011-02-16 ニコックス エスエー ニトロソ化プロトンポンプ阻害剤、組成物および使用方法
GB2394895A (en) * 2002-11-06 2004-05-12 Cipla Ltd Proton pump inhibitor composition in paste form
WO2005000269A1 (en) * 2003-06-26 2005-01-06 Cipla Limited Pharmaceutical formulations comprising a proton pump inhibitor
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2006026829A1 (en) * 2004-09-09 2006-03-16 Metelli Pty Ltd Stable paste composition of enteric coated acid labile active agent and use thereof
CN101500553B (zh) * 2006-07-25 2012-04-18 维克塔有限公司 联合使用小分子二羧酸的衍生物与ppi用于抑制胃酸分泌的组合物和方法
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
IN2012DN00359A (pt) 2009-07-20 2015-05-22 Vetegen Llc
US8722636B2 (en) 2011-01-31 2014-05-13 New Market Pharmaceuticals, LLC Animal treatments
WO2013165468A1 (en) * 2012-05-02 2013-11-07 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
US10064849B2 (en) 2012-05-02 2018-09-04 New Market Pharmaceuticals Pharmaceutical compositions for direct systemic introduction
GB2524351B (en) * 2013-10-18 2016-12-14 Norbrook Lab Ltd Proton Pump Inhibitor Paste Compositions
EP3057571B1 (en) * 2013-10-18 2019-03-06 Norbrook Laboratories Limited Proton pump inhibitor paste compositions
FI3386507T3 (fi) 2015-12-08 2023-09-06 Luoda Pharma Ltd Menetelmiä ja koostumuksia mahahaavojen hoitoon
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CA3033065A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS
ES2723873B1 (es) * 2018-03-01 2020-05-13 Hernan Ma Carmen Batanero Medicamento combinado con omeprazol y vitamina B12
CN112972481A (zh) * 2021-03-18 2021-06-18 华农（肇庆）生物产业技术研究院有限公司 药物组合物及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4255432A (en) 1979-09-06 1981-03-10 Syntex (U.S.A.) Inc. 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
DK130287D0 (da) 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors

Also Published As

Publication number Publication date
EP1156806B1 (en) 2004-04-07
EA004683B1 (ru) 2004-06-24
SK12062001A3 (sk) 2001-12-03
DE60009675T2 (de) 2005-03-24
DK1156806T3 (da) 2004-08-02
BR0008403A (pt) 2002-01-29
CN1341022A (zh) 2002-03-20
CN1227009C (zh) 2005-11-16
KR20010102297A (ko) 2001-11-15
NZ512771A (en) 2003-02-28
AU771061B2 (en) 2004-03-11
KR100701448B1 (ko) 2007-03-30
PL195783B1 (pl) 2007-10-31
ES2216870T3 (es) 2004-11-01
NO20014074L (no) 2001-08-22
EA200100905A1 (ru) 2002-02-28
CO5140102A1 (es) 2002-03-22
HK1041650A1 (en) 2002-07-19
IL144131A0 (en) 2002-05-23
HUP0200325A3 (en) 2003-05-28
ATE263562T1 (de) 2004-04-15
PT1156806E (pt) 2004-07-30
ME00864B (me) 2008-09-29
RS50023B (sr) 2008-09-29
CZ301647B6 (cs) 2010-05-12
EP1156806A1 (en) 2001-11-28
JP2002537337A (ja) 2002-11-05
HRP20010615A2 (en) 2002-12-31
TW587936B (en) 2004-05-21
NO328863B1 (no) 2010-05-31
BG105754A (en) 2002-03-29
DE60009675D1 (de) 2004-05-13
NO20014074D0 (no) 2001-08-22
AU3368700A (en) 2000-09-14
CA2362932A1 (en) 2000-08-31
HU228181B1 (en) 2013-01-28
ZA200106104B (en) 2002-12-24
CA2362932C (en) 2010-11-30
CZ20013058A3 (cs) 2001-11-14
SK286371B6 (sk) 2008-08-05
HUP0200325A2 (en) 2002-06-29
WO2000050038A1 (en) 2000-08-31
US6316481B1 (en) 2001-11-13
AR029615A1 (es) 2003-07-10
YU50401A (sh) 2004-05-12
BG65291B1 (bg) 2007-12-28
PL350729A1 (en) 2003-01-27

Similar Documents

Publication Publication Date Title
HRP20010615B1 (en) Pharmaceutical compositions containing proton pump inhibitors
TW200531696A (en) Pharmaceutical formulations of bisphosphonates
BR9714310A (pt) Composição farmacêutica
DE60041976D1 (de) Phenoxycarbonsäureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
TNSN05189A1 (en) Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
ES2062543T3 (es) Formulaciones farmaceuticas.
ATE293970T1 (de) Lipasehemmer enthaltende pharmazeutische zusammensetzungen
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
NO20014719D0 (no) Orale farmasöytiske preparater inneholdende lang-kjedete triglyserider og lipofile overflateaktive midler
ES2192234T3 (es) Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos.
UY26303A1 (es) Composiciones farmacéuticas para administración oral y tópica
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ES2140512T3 (es) Composiciones farmaceuticas que contienen derivados de estaurosporina y un gliceridos polialquilenglicolico.
AR006833A1 (es) Compuestos de beta lactama monociclicos, composicion farmaceutica que los contiene, uso de dichos compuestos para preparar medicamentos, procedimientopara preparar dichos compuestos, compuestos intermediarios y procedimientos para preparar dichos compuestos intermediarios.
DE60042831D1 (de) Pharmazeutisch aktive sulfonylaminosäurederivate
PE4398A1 (es) Composiciones farmaceuticas que incrementan la biodisponibilidad de inhibidores de proteinasas
ES2143833T3 (es) Acidos y esteres de la diosmetina y composiciones farmaceuticas que los contienen.
ES2173360T3 (es) Agentes odoriferos y/o aromaticos.
AR016212A1 (es) Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
ATE395049T1 (de) Verbesserte pharmazeutische zusammensetzungen von hiv-proteasehemmern
IT1292126B1 (it) Esteri cerosi arricchiti in acidi grassi omega-3 insaturi,loro preparazione ed uso
BRPI9908132B8 (pt) composição farmacêutica líquida para administração oral
DE60112578D1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
DE3778826D1 (de) Bestaendige therapeutische zusammensetzungen, basierend auf hydrophobem pflanzlichem oel und verfahren zu ihrer herstellung.

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: MERCK SHARP & DOHME CORP., US

B1PR Patent granted
PNAN Change of the applicant name, address/residence

Owner name: SCHERING CORPORATION, US

Owner name: MERCK SHARP & DOHME CORP., US

ODRP Renewal fee for the maintenance of a patent

Payment date: 20190129

Year of fee payment: 20

PB20 Patent expired after termination of 20 years

Effective date: 20200218